# Differential Responsiveness of Human Skin Mast Cells to SCF and IL-33: Reduced Reactivity to SCF but Not to IL-33 in the Post-Mitotic Phase

**Authors:** Manqiu Jin, Jean Schneikert, Anja Wegner, Torsten Zuberbier, Magda Babina

PMC · DOI: 10.3390/cells15050398 · Cells · 2026-02-24

## TL;DR

Human skin mast cells respond differently to SCF and IL-33, with reduced SCF sensitivity and increased IL-33 sensitivity in non-dividing cells.

## Contribution

Identifies distinct signaling and cytokine responses to SCF and IL-33 in dividing versus post-mitotic human skin mast cells.

## Key findings

- Post-mitotic mast cells show reduced responsiveness to SCF but maintain cytokine production.
- IL-33 induces stronger cytokine release and activates different signaling pathways compared to SCF.
- Non-dividing mast cells become more sensitive to IL-33, possibly as a compensatory adaptation.

## Abstract

Skin mast cells (MCs) play a vital role in acute allergic reactions and also contribute to chronic dermatoses partially through cytokine production. Key growth factors (GFs), such as SCF and IL-33, orchestrate MC survival and activity. Whether early responses differ between these factors remains incompletely defined. In the skin, MCs are long-lived and can proliferate outside the body but eventually exit the cell cycle. It remains unclear whether post-mitotic MCs show altered sensitivity to GFs. MCs were isolated from human foreskin and cultured in the presence of SCF + IL-4. GF-deprived cells were stimulated with either SCF or IL-33. Signaling events were determined by immunoblot. Gene expression was studied by RT-qPCR, cytokine release by ELISA, comparing dividing (3–4 weeks) with post-mitotic “aged” MCs (≥6 weeks). SCF strongly induced genes like FOS, EGR1, and NR4A2, while IL-33 was particularly effective at inducing JUN. IL-33 also prompted significant cytokine production (TNF-α, CCL1 and IL-13), whereas the activation of LIF was confined to SCF. SCF favored KIT, ERK, AKT, and STAT5 activation, whereas IL-33 preferentially stimulated JNK and p38 pathways. Although post-mitotic MCs showed diminished overall responsiveness to SCF, and with interesting differences among modules, their cytokine response to SCF remained comparable. Intriguingly, after exiting the cell cycle, MCs showed heightened sensitivity to IL-33, evidenced by increased ERK activation and TNF-α production. Collectively, IL-33 and SCF elicit markedly different early responses in human skin MCs. Chronic exposure to SCF reduces the responsiveness to this GF without eliminating their reactivity, while non-dividing MCs become more sensitive to IL-33, possibly as a compensatory adaptation.

## Linked entities

- **Genes:** FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353], EGR1 (early growth response 1) [NCBI Gene 1958], NR4A2 (nuclear receptor subfamily 4 group A member 2) [NCBI Gene 4929], JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725], LIF (LIF interleukin 6 family cytokine) [NCBI Gene 3976], KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815], EPHB2 (EPH receptor B2) [NCBI Gene 2048], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], STAT5A (signal transducer and activator of transcription 5A) [NCBI Gene 6776], MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599], CRK (CRK proto-oncogene, adaptor protein) [NCBI Gene 1398]
- **Proteins:** KITLG (KIT ligand), IL33 (interleukin 33), IL4 (interleukin 4), TNF (tumor necrosis factor), CCL1 (C-C motif chemokine ligand 1), IL13 (interleukin 13)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CCL1 (C-C motif chemokine ligand 1) [NCBI Gene 6346] {aka I-309, P500, SCYA1, SISe, TCA3}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, STAT5A (signal transducer and activator of transcription 5A) [NCBI Gene 6776] {aka MGF, STAT5}, IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, KITLG (KIT ligand) [NCBI Gene 4254] {aka DCUA, DFNA69, FPH2, FPHH, KL-1, Kitl}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, NR4A2 (nuclear receptor subfamily 4 group A member 2) [NCBI Gene 4929] {aka HZF-3, IDLDP, NOT, NURR1, RNR1, TINUR}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, EGR1 (early growth response 1) [NCBI Gene 1958] {aka AT225, G0S30, KROX-24, NGFI-A, TIS8, ZIF-268}, LIF (LIF interleukin 6 family cytokine) [NCBI Gene 3976] {aka CDF, DIA, HILDA, MLPLI}
- **Diseases:** dermatoses (MESH:D012871)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12984688/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12984688/full.md

## References

110 references — full list in the complete paper: https://tomesphere.com/paper/PMC12984688/full.md

---
Source: https://tomesphere.com/paper/PMC12984688